Company: BLLN
Filing Date: 2025-08-11
Form Type: DRS/A
Source: 0000950123-25-007483
Chunk: 206

Company: BillionToOne, Inc.
Filing Date: 2025-08-11
Form: DRS/A
Chunk 206
---
 additional clinical studies of the assay performance in lung and liver cancer cohorts were published in Clinical Lung Cancerand the Journal of American College of Surgeons,respectively. The analytical and clinical validation of Northstar Select, including the head-to-headcomparison against other on-marketassays is currently under peer review. Beyond the peer-reviewed journal publications below, we have published posters and abstracts at various medical conferences including AACR, AACR LBx, ASCO, and the International Society of Liquid Biopsy.

| 61 |     | Choudhury, Y., Tan, M.-H., Shi, J. L., Tee, A., Ngeow, K. C., Poh, J., Goh, R. R., & Mong, J. (2022). Complementing tissue testing with plasma mutation profiling improves therapeutic decision-making for patients 
 with lung cancer. Frontiers in Medicine, 9, 758464.                                                                                                                                                                 |

149

PRENATAL nature scientific reports A novel high-throughput molecular counting method with single base pair resolution enables accurate single-gene NIPT American Journal of Hematology Accurately identified all affected pregnancies as high risk at a greater than 9 in 10 risk Top 10 of 2023 award by AJHG* JME Journal of Medical Economics The cost to detect one affected pregnancy by UNITY Fetal Risk Screen was 62% lower than traditional carrier screening Genetics inMedicine 99.4% NPV and >90% sensitivity in a high risk population nature scientific reports Analytical sensitivity and specificity of >99.9% OBSTETRICS& GYNECOLOGY 100% concordance to 465 neonatal outcomes OBSTETRICS& GYNECOLOGY 100% concordance to 401 RhD neonatal outcomes ONCOLOGY CelPress Absolute quantification of cell-free DNA for prenatal genetics and oncology Clinical Lung Cancer Brief Report: Methylation-Based ctDNA Serial Monitoring Correlates With Immunotherapy Response in NSCLC PRENATAL DIAGNOSIS Assay sensitivity of 96% and NPV of 99.8%.9-out-of 10 results were confirmed to be affected via neonatal outcomes Annals of Gynecology and Obstetrics Research 99.7% sensitivity, 99.9% specificity. 80% of patients were <35 years Johnson&Johnson A Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (H